ESPR Q3 2018 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

ESPREsperion Therapeutics, Inc.

$519M

Q3 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$0

Gross Profit

-$42M

Operating Income

-$51M

Net Income

-$50M

EPS (Diluted)

$-1.86

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$38M

Free Cash Flow

-$38M

Stock-Based Comp.

$5M

Balance Sheet

Total Assets

$174M

Total Liabilities

$42M

Stockholders' Equity

$132M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$42M	$0	—
Operating Income	-$51M	-$46M	-10.5%
Net Income	-$50M	-$45M	-10.4%